CASC3 and neoplasm: Combinational treatment induced greater tumor inhibition than treatment with BTZ or DCZ3301 alone (Fig. 6a and b), indicating that the treatment of BTZ-resistant cells with DCZ3301 could restore the sensitivity to BTZ in vivo.